An update on medication management of women with schizophrenia in pregnancy

Carolyn Breadon, Jayashri Kulkarni

Research output: Contribution to journalReview ArticleOtherpeer-review

Abstract

Introduction: Women with schizophrenia and their babies are at high risk of adverse outcomes in pregnancy and childbirth. A better understanding of the specific risks conferred by the illness itself and by the treatment provided will help guide more effective care of these women. Areas covered: Herein, the authors review genetic, demographic, socioeconomic, nutritional and lifestyle risks associated with schizophrenia in pregnancy. They also cover specific risks associated with typical antipsychotic medications, specific risks associated with atypical antipsychotic medications, risks associated with polypharmacy and risks of developmental delay in children exposed to antipsychotic medications in utero. Expert opinion: Our understanding of the risks that women with schizophrenia face in pregnancy from their illness and from the treatment they receive continues to evolve. As our ability to analyze data progresses, the risks conferred by antipsychotic medication treatment appear to lessen in clinical and statistical significance, whilst the true risks to these women and their babies from their experience of disadvantage continue to set them aside from the general population. Reducing polypharmacy and providing comprehensive and supportive care can minimize harm to women with schizophrenia and their babies.

Original languageEnglish
Pages (from-to)1365-1376
Number of pages12
JournalExpert Opinion on Pharmacotherapy
Volume20
Issue number11
DOIs
Publication statusPublished - 24 Jul 2019

Keywords

  • Atypical antipsychotic
  • congenital abnormalities
  • gestational diabetes
  • maternal obesity
  • neonatal abstinence syndrome
  • neonatal respiratory distress
  • pregnancy
  • schizophrenia
  • typical antipsychotic

Cite this

@article{2b0d3219384347828ac563fc29217132,
title = "An update on medication management of women with schizophrenia in pregnancy",
abstract = "Introduction: Women with schizophrenia and their babies are at high risk of adverse outcomes in pregnancy and childbirth. A better understanding of the specific risks conferred by the illness itself and by the treatment provided will help guide more effective care of these women. Areas covered: Herein, the authors review genetic, demographic, socioeconomic, nutritional and lifestyle risks associated with schizophrenia in pregnancy. They also cover specific risks associated with typical antipsychotic medications, specific risks associated with atypical antipsychotic medications, risks associated with polypharmacy and risks of developmental delay in children exposed to antipsychotic medications in utero. Expert opinion: Our understanding of the risks that women with schizophrenia face in pregnancy from their illness and from the treatment they receive continues to evolve. As our ability to analyze data progresses, the risks conferred by antipsychotic medication treatment appear to lessen in clinical and statistical significance, whilst the true risks to these women and their babies from their experience of disadvantage continue to set them aside from the general population. Reducing polypharmacy and providing comprehensive and supportive care can minimize harm to women with schizophrenia and their babies.",
keywords = "Atypical antipsychotic, congenital abnormalities, gestational diabetes, maternal obesity, neonatal abstinence syndrome, neonatal respiratory distress, pregnancy, schizophrenia, typical antipsychotic",
author = "Carolyn Breadon and Jayashri Kulkarni",
year = "2019",
month = "7",
day = "24",
doi = "10.1080/14656566.2019.1612876",
language = "English",
volume = "20",
pages = "1365--1376",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Taylor & Francis",
number = "11",

}

An update on medication management of women with schizophrenia in pregnancy. / Breadon, Carolyn; Kulkarni, Jayashri.

In: Expert Opinion on Pharmacotherapy, Vol. 20, No. 11, 24.07.2019, p. 1365-1376.

Research output: Contribution to journalReview ArticleOtherpeer-review

TY - JOUR

T1 - An update on medication management of women with schizophrenia in pregnancy

AU - Breadon, Carolyn

AU - Kulkarni, Jayashri

PY - 2019/7/24

Y1 - 2019/7/24

N2 - Introduction: Women with schizophrenia and their babies are at high risk of adverse outcomes in pregnancy and childbirth. A better understanding of the specific risks conferred by the illness itself and by the treatment provided will help guide more effective care of these women. Areas covered: Herein, the authors review genetic, demographic, socioeconomic, nutritional and lifestyle risks associated with schizophrenia in pregnancy. They also cover specific risks associated with typical antipsychotic medications, specific risks associated with atypical antipsychotic medications, risks associated with polypharmacy and risks of developmental delay in children exposed to antipsychotic medications in utero. Expert opinion: Our understanding of the risks that women with schizophrenia face in pregnancy from their illness and from the treatment they receive continues to evolve. As our ability to analyze data progresses, the risks conferred by antipsychotic medication treatment appear to lessen in clinical and statistical significance, whilst the true risks to these women and their babies from their experience of disadvantage continue to set them aside from the general population. Reducing polypharmacy and providing comprehensive and supportive care can minimize harm to women with schizophrenia and their babies.

AB - Introduction: Women with schizophrenia and their babies are at high risk of adverse outcomes in pregnancy and childbirth. A better understanding of the specific risks conferred by the illness itself and by the treatment provided will help guide more effective care of these women. Areas covered: Herein, the authors review genetic, demographic, socioeconomic, nutritional and lifestyle risks associated with schizophrenia in pregnancy. They also cover specific risks associated with typical antipsychotic medications, specific risks associated with atypical antipsychotic medications, risks associated with polypharmacy and risks of developmental delay in children exposed to antipsychotic medications in utero. Expert opinion: Our understanding of the risks that women with schizophrenia face in pregnancy from their illness and from the treatment they receive continues to evolve. As our ability to analyze data progresses, the risks conferred by antipsychotic medication treatment appear to lessen in clinical and statistical significance, whilst the true risks to these women and their babies from their experience of disadvantage continue to set them aside from the general population. Reducing polypharmacy and providing comprehensive and supportive care can minimize harm to women with schizophrenia and their babies.

KW - Atypical antipsychotic

KW - congenital abnormalities

KW - gestational diabetes

KW - maternal obesity

KW - neonatal abstinence syndrome

KW - neonatal respiratory distress

KW - pregnancy

KW - schizophrenia

KW - typical antipsychotic

UR - http://www.scopus.com/inward/record.url?scp=85068662649&partnerID=8YFLogxK

U2 - 10.1080/14656566.2019.1612876

DO - 10.1080/14656566.2019.1612876

M3 - Review Article

VL - 20

SP - 1365

EP - 1376

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 11

ER -